InspireMD’s CGuard embolic prevention system has posted positive results in the PARADIGM study, led by principal investigator Piotr Musialek, as reported at the EuroPCR 2015 meeting (19–22 May, Paris, France).
Presented for the first time at EuroPCR 2015 (19–22 May, Paris, France) during the “Hot line” session on peripheral interventions, new clinical data from two different studies show that the IN.PACT Admiral drug-coated balloon from Medtronic successfully treated long lesions in the superficial femoral and popliteal arteries.
Shockwave Medical has announced US$40m in funding, co-led by returning investor Sofinnova Partners and new investor Venrock, with the participation of RA Capital, Deerfield, Sectoral Asset Management, Ally Bridge Group, and two undisclosed large-cap strategic investors.
Silk Road Medical has announced that the company has received premarket approval (PMA) from the US Food & Drug Administration (FDA) for the Enroute transcarotid stent system. The Enroute transcarotid stent is the first carotid stent that is introduced and implanted into the carotid artery through a direct common carotid access point to enable a safe and more direct approach to carotid artery stenting.
Nitiloop has received FDA clearance for its first product, NovaCross, which is intended to be used in conjunction with a guidewire to access discrete regions of the coronary or peripheral vasculature.
Delcath has announced that abstracts summarising the data from two European studies of treatment with the Delcath Hepatic Chemosat Delivery System will be presented at the upcoming Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting (to be held in Lisbon, Portugal, 26–30 September).
The US Centers for Medicare & Medicaid Services (CMS) has approved the removal of offset charges associated with pass-through payment for drug-coated balloons (DCBs) under Medicare outpatient prospective payment system.
Edixomed presented its interim data from the ProNOx 1 study at the 7th International Symposium on the Diabetic Foot (20–23 May, The Hague, the Netherlands).
The World Conference on Interventional Oncology (WCIO) is developing an online interventional oncology curriculum called IO University. Michael Soulen, immediate past chair of the WCIO, told Interventional News: “One of the gaps in interventional radiology training is in oncology education. If you do an interventional radiology fellowship, you receive very little education in oncology; you learn how to do procedures, but you do not learn about cancer or what the other specialists do. You do not learn to be an effective participant in the oncology scene. The IO University is designed to address these gaps.”
Biotronik has announced the publication of promising clinical results regarding its Pulsar-18 stent platform. Adding to the data collected in the earlier 4EVER1 and PEACE2 trials, the new results published in Clinical Medical Insights: Cardiology further confirm the safety and efficacy of the Pulsar-18 self-expanding nitinol stent, with positive patency results for very challenging cases of femoropopliteal disease.
Non-thermal, non-tumescent technologies to treat varicose veins were shown to have comparable short-term outcomes to those obtained with thermal technologies at the recent Charing Cross Symposium (28 April–1 May, London, UK).
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending the use of Eliquis (apixaban) as an option for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults.
Baxter International has announced it is voluntarily recalling four product codes of its Vascu-Guard Peripheral Vascular Patch.
A new line of medical devices has the potential to save the lives of millions of haemodialysis patients and billions of dollars’ worth of secondary medical treatments, NuVascular Technologies has announced. The suite of products uses NuVascular’s patented nanotechnology to develop devices such as access grafts and sutures that can be loaded with specific drugs to treat patients afflicted with kidney disease by delivering the drug directly to a precise site for a defined period of time while significantly reducing the risks associated with these types of devices.
Cardinal Health announced on 28 May 2015 that its 1 March 2015 binding offer to acquire Johnson & Johnson’s Cordis business for US$1.944 billion in cash was formally accepted.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos